Sunlenca Side Effects
Generic name: lenacapavir
Medically reviewed by Drugs.com. Last updated on Mar 24, 2024.
Note: This document contains side effect information about lenacapavir. Some dosage forms listed on this page may not apply to the brand name Sunlenca.
Applies to lenacapavir: oral tablet. Other dosage forms:
Serious side effects of Sunlenca
Along with its needed effects, lenacapavir (the active ingredient contained in Sunlenca) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking lenacapavir:
Incidence not known
- Dark urine
- fever
- inability to move the arms and legs
- joint pain
- light-colored stools
- muscle tenderness, weakness, or pain
- nausea and vomiting
- skin rash
- sudden numbness and weakness in the arms and legs
- unusual tiredness or weakness
- upper right abdominal or stomach pain
- weight loss
- yellow eyes and skin
For Healthcare Professionals
Applies to lenacapavir: oral tablet, subcutaneous solution.
Gastrointestinal
Common (1% to 10%): Nausea[Ref]
General
The most common adverse reactions reported in at least 3% patients were nausea and injection site reactions.[Ref]
Hepatic
Common (1% to 10%): Increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased direct bilirubin[Ref]
Local
Very common (10% or more): Injection site reactions (65%) [include swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%) discomfort (1%), mass (3%), hematoma (1%), edema (1%) and ulcer (1%)][Ref]
Four percent patients experienced Grade 3 ISRs (erythema, pain, swelling)[Ref]
Metabolic
Common (1% to 10%): Glycosuria, hyperglycemia, proteinuria[Ref]
Musculoskeletal
Very common (10% or more): Increased creatinine (13%)[Ref]
More about Sunlenca (lenacapavir)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antivirals
- Breastfeeding
- En español
Patient resources
- Sunlenca drug information
- Sunlenca oral/injection
- Sunlenca (Lenacapavir Oral) (Advanced Reading)
- Sunlenca (Lenacapavir Subcutaneous) (Advanced Reading)
Professional resources
Related treatment guides
References
1. Product Information. Sunlenca (lenacapavir). Gilead Sciences. 2022.
2. Product Information. Sunlenca (lenacapavir). Gilead Sciences Pty Ltd. 2023;SUNLENCA Product Inf.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.